The role of proB-type natriuretic peptide (proBNP) for the diagnosis of congestive heart failure (CHF) among patients presenting to the Emergency Department (ED) with dyspnea remains undefined. Accordingly, in the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study, we are systematically assessing the value of proBNP (Elecsys ® proBNP Immunoassay, Roche Diagnostics Corporation) for the urgent evaluation of dyspneic patients with suspected acute CHF. Methods/Results: Enrollment for the PRIDE study has closed, and clinical follow up is to complete in October, 2003. The PRIDE study is a single-center, prospective, blinded trial of 600 patients, age >21 years, presenting with a complaint of dyspnea to an urban ED. Exclusion criteria include severe renal insufficiency (serum creatinine >2.5 mg/dl), ST segment depression or elevation on ECG, dyspnea following trauma, and >2 hours following urgent administration of intravenous loop diuretic. Following informed consent, information regarding demographics, past medical history, current medications, and presentation of each patient was gathered. A specimen of blood was collected for blinded proBNP measurement. At the end of standard clinical assessment (history, physical exam, ECG, chest x-ray), the treating ED physician provided a clinical estimate of the presence of CHF as the cause of dyspnea. The primary endpoint of the study will be a comparison of the predictive value of proBNP measurement versus clinical judgment for the presence of CHF at the time of clinical evaluation in the ED. Other endpoints will include correlation of proBNP levels with the diagnosis of CHF from presentation to 60 days of follow-up, as well as correlations with hospital length of stay.
Background. The negative inotrope and upregulation of β 3 -adrenergic receptors (AR) in failing human and animal hearts suggest a direct and contributing role of cardiac β 3 -AR activation on heart failure (HF) progression. Therefore, we tested the hypothesis that chronic β 3 -AR blockade may limit or prevent the progression of HF. Methods. Left ventricular (LV) and myocyte functional response and β 1 -and β 3 -AR expression were compared in 3 groups of rats (6 each) for a period of 4 months: 1) Isoproterenol (ISO)-treated, 4 months after receiving ISO (340 mg/kg, sq, for 2 days); 2) ISO/β 3 -ANT, one month after receiving ISO, L-748,337, a selective β 3 -AR antagonist (β 3 -ANT) (10 -7 M/kg/day by implanted osmotic mini pump) was initiated after the onset of HF and was given for 2 months; and 3) sham controls. Results. Compared with controls, ISO-treated rats had HF onset at one month after ISO and progressed to severe CHF at 4 months. Plasma norepinephrine (NE, 1482 vs 247 pg/ml) increased 6 fold. Both stroke volume (SV) and ejection fraction (EF, 34 vs 62%) decreased more than 45%, and LV end-diastolic pressure (P ED , 16.3 vs 6.4 mmHg) doubled, parallel with 49% reductions in cell contraction (dL/dt max, 95 vs 189 µm/s) and relaxation (dR/dt max ,75 vs 158 µm/s) and a much less increase in dL/dt max (32 vs 74%) in response to superfusion of ISO (10 -8 M). These changes were associated with significantly decreased β 1 -AR mRNA (52%, 0.30 vs 0.62), but increased β 3 -AR mRNA (119%, 1.25 vs 0.57) expression. Treatment with β 3 -ANT significantly decreased P ED and plasma NE (197 pg/ml). Both SV and EF (59%) increased to more than 75% from ISOtreated values. The signal ratios of β 1 -AR mRNA (0.59) and β 3 -AR mRNA (0.66) remained close to control levels. ISO-induced increase in dL/dt max (75%) was also significantly augmented. Conclusion. Chronic β 3 -ANT causes normalization of β 1 -and β 3 -AR gene expression, restores normal responsiveness of myocyte to ß-AR stimulation, and leads to regression of LV and myocyte dysfunction in a rat model of progressive CHF. Thus, β 3 -AR blocker may provide a new therapeutic strategy for the treatment of CHF. 
